Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas.

Edwards, Jarem; Ferguson, Peter M; Lo, Serigne N; Pires da Silva, Ines; Colebatch, Andrew J; Lee, Hansol; Saw, Robyn Pm; Thompson, John F; Menzies, Alexander M; Long, Georgina V; Newell, Felicity; Pearson, John; Waddell, Nicola; Hayward, Nicholas; Johansson, Peter A; Mann, Graham; Scolyer, Richard A; Palendira, Umaimainthan; Wilmott, James S

Tumor mutation burden (TMB) has been proposed as a key determinant of immunogenicity in several cancers, including melanoma. The evidence presented thus far, however, is often contradictory and based mostly on RNA-sequencing data for the quantification of immune cell phenotypes. Few studies have investigated TMB across acral, mucosal, and cutaneous melanoma subtypes, which are known to have different TMB. It is also unknown whether chromosomal structural mutations (SVs) contribute to the immunogenicity in acral and mucosal melanomas where such aberrations are common. We stained 151 cutaneous and 35 acral and mucosal melanoma patient samples using quantitative IHC and correlated immune infiltrate phenotypes with TMB and other genomic profiles. TMB and SVs did not correlate with the densities of CD8+ lymphocytes, CD103+ tumor-resident T cells (Trm), CD45RO+ cells, and other innate and adaptive immune cell subsets in cutaneous and acral/mucosal melanoma tumors, respectively, including in analyses restricted to the site of disease, and in a validation cohort. In 43 stage III treatment-naïve cutaneous melanoma patients, we found that the density of immune cells, particularly Trm, was significantly associated with patient survival but not with TMB. Overall, TMB and chromosomal structural aberrations are not associated with protective antitumor immunity in treatment-naïve melanoma.